Executive Summary

Datroway (datopotamab deruxtecan-dlnk), a TROP2-directed antibody–drug conjugate (ADC) jointly developed by Daiichi Sankyo and AstraZeneca, has recently been approved by the U.S. FDA for first-line treatment of metastatic triple-negative breast cancer (TNBC) in patients ineligible for PD-1/PD-L1 inhibitors. This landmark approval (May 22, 2026) was based on the pivotal Phase III TROPION-Breast02 trial, which demonstrated clinically meaningful survival benefits over standard chemotherapy in this high-need population (^[1]) (^[2]). Patients receiving Datroway achieved a median progression-free survival (PFS) of 10.8 vs 5.6 months (HR=0.57, p<0.0001) and median overall survival (OS) of 23.7 vs 18.7 months (HR=0.79, p=0.029) compared to chemotherapy (^[1]). The objective response rate (ORR) was 64% vs 30% (^[3]), with a median duration of response (DoR) of 12.3 vs 7.1 months (^[4]). The safety profile was manageable (Grade ≥3 TRAEs 33% vs 29% (^[5])), with fewer treatment discontinuations than chemotherapy.

These robust results position Datroway to potentially replace traditional chemotherapy as the new standard of care for the ~70% of metastatic TNBC patients who cannot receive immunotherapy (^[6]) (^[7]). The FDA approval was granted under Project Orbis (concurrent review with Australia, Canada, Singapore and Switzerland) (^[8]) (^[9]). Regulatory submissions are underway globally: for example, an EU variation was validated in Dec 2025 (^[6]). Datroway’s approval will directly compete with sacituzumab govitecan (Trodelvy), Gilead’s TROP2-ADC which also recently showed PFS benefit in first-line TNBC (^[10]). However, Datroway is the only agent to date to show a statistically significant OS benefit in this setting (^[11]) (^[2]), which industry analysts believe will be a key differentiator.

This report provides a comprehensive analysis of Datroway’s approval and launch. We review the historical and clinical context of metastatic TNBC, detail the design and results of the TROPION-Breast02 trial, and compare these data to other frontline therapies (e.g. sacituzumab). We examine the strategic implications for AstraZeneca/Daiichi Sankyo, including pricing and market access plans, competitor landscape, and projected uptake. Case vignettes cover expert commentary (e.g. NCCN guideline updates and patient advocacy perspectives) and real-world considerations such as patient eligibility and payer coverage issues. Finally, we discuss future directions (expansions, combinations, and long-term impact on survival) and conclude with the broad significance of Datroway’s arrival in TNBC therapy. All claims are backed by published data and official sources.

Introduction and Background

Metastatic TNBC and Unmet Need: Triple-negative breast cancer (TNBC) – lacking ER/PR/HER2 expression – accounts for ~10–20% of breast cancers (^[12]). It is an aggressive subtype with early relapses, visceral metastases (including brain), and poor prognosis (^[12]). Historically, chemotherapy has been the mainstay. Only a minority of patients (≈30–40%) have PD-L1–positive tumors eligible for immune checkpoint inhibitors (e.g. pembrolizumab) (^[6]) (^[13]), leaving the majority (~70%) dependent on chemotherapy (^[6]) (^[7]). Moreover, nearly half of metastatic TNBC patients never reach second-line therapy in real-world practice, underscoring the limited durability of front-line chemo and the urgent need for better options (^[14]).

Evolving Treatment Landscape: Recent years have seen some advances. For PD-L1–positive TNBC, pembrolizumab with chemotherapy improved PFS (e.g. KEYNOTE-355) and is now standard first-line. PARP inhibitors (olaparib, talazoparib) have benefits in BRCA-mutated TNBC. Yet for the ~70% of patients who are PD-L1–negative or cannot receive immunotherapy (due to contraindications or access), no therapy until now conclusively improved survival beyond chemo. Sacituzumab govitecan (Trodelvy), a TROP2-ADC, is FDA-approved in later lines (≥2L) of metastatic TNBC (based on ASCENT trial) but been investigational in first line (e.g. ASCENT-03/04). Notably, two large Phase III trials in 2025 (TROPION-Breast02 and ASCENT-03) have shown that TROP2-directed ADCs can significantly improve outcomes early in TNBC (^[10])(^[15]).

Datroway (Datopotamab Deruxtecan): Datroway (datopotamab deruxtecan-dlnk; “Dato-DXd”) is a TROP2-directed ADC discovered by Daiichi Sankyo. It couples a humanized anti-TROP2 antibody to a potent topoisomerase-I inhibitor payload via a cleavable linker. Importantly, TROP2 is widely expressed on breast cancer cells, making it an attractive target (^[14]) (^[16]). Dato-DXd earned its first FDA approval in Jan 2025 for second-line HR+/HER2- metastatic breast cancer, based on the TROPION-Breast01 trial which showed a strong PFS advantage (HR 0.63) over chemo (^[17]) and a favorable safety profile. That success established Dato-DXd as an Enhertu “successor” in the breast cancer ADC space (^[18]) (^[17]). The drug’s label in HR+ is indicated “after endocrine and chemotherapy for metastatic disease.” Dato-DXd also won an accelerated approval in June 2025 for EGFR-mutant NSCLC after multiple prior therapies (based on ORR data) (^[19]).

Against this backdrop, TROPION-Breast02 was launched to test Dato-DXd upfront in TNBC patients with no prior systemic therapy for metastatic disease – specifically targeting those for whom immunotherapy is not an option (^[20]) (^[14]). The U.S. supplemental BLA was accepted in Feb 2026 (Priority Review with PDUFA date June 2) (^[20]). EMA an EU “Type II Variation” was validated in Dec 2025 for filing. On May 22, 2026, following FDA review (and EMA review underway), Datroway was approved for this new TNBC indication (^[21]). This report examines all relevant data from the pivotal trial and situates this approval within the competitive and commercial context, as well as future implications.

TROPION-Breast02 Trial: Design and Results

TROPION-Breast02 (NCT05374512) was a global, randomized Phase III trial designed to evaluate first-line datopotamab deruxtecan versus standard chemotherapy (“investigator’s choice”) in metastatic TNBC patients who had not received prior systemic therapy for metastatic disease and could not receive PD-1/PD-L1 inhibitors (^[11]) (^[22]). This included both patients whose tumors were PD-L1-negative and PD-L1-positive patients deemed ineligible for checkpoint inhibitors (e.g. due to prior adjuvant immunotherapy, comorbidities, or local unavailability) (^[11]). Key eligibility: age ≥18, ECOG 0–1, at least one measurable lesion, no prior metastatic therapy, no active interstitial lung disease, etc. The trial enrolled 644 patients across 23 countries (^[23]): 323 randomized to Dato-DXd (6 mg/kg IV Q3W) and 321 to physician’s choice chemo. Chemotherapy options included weekly paclitaxel, nab-paclitaxel, capecitabine, eribulin, or carboplatin, per investigator discretion (^[24]). Randomization was stratified by region (US/Europe vs RoW), PD-L1 status, and disease-free interval.

Endpoints: The dual primary endpoints were progression-free survival (PFS) by blinded independent central review (BICR, RECIST v1.1) and overall survival (OS) (^[25]). Secondary endpoints included ORR, DoR, safety, etc.

Efficacy Results: In a median follow-up of ~27.5 months (data cut Aug 25, 2025) (^[26]) (^[23]), Datroway showed statistically significant and clinically meaningful improvements in both co-primary endpoints. Median PFS (BICR) was 10.8 vs 5.6 months (HR = 0.57; 95% CI, 0.44–0.73; p<0.0001) (^[27]), translating to a 43% reduction in risk of progression or death. Median OS was 23.7 vs 18.7 months (HR = 0.79; 95% CI, 0.64–0.98; p = 0.029) (^[27]) – a 5.0-month absolute gain in median survival. (As an independent confirmation, the FDA press release reported essentially identical values: PFS 10.8 vs 5.6 mo, OS 23.7 vs 18.7 mo, HR 0.57 and 0.79 respectively (^[1]).) Both endpoints crossed their statistical thresholds. Subgroup analyses showed consistent benefit across stratifications (e.g. PD-L1 status, region).

Additional outcomes: Confirmed objective response rate by BICR was 64% vs 30% favoring Datroway (^[3]). The median duration of response was 12.3 vs 7.1 months (^[4]). Datroway nearly doubled both ORR and DoR compared to chemo. These data are summarized below.

【Table 1: Efficacy in TROPION-Breast02 (Datroway vs Chemo) vs ASCENT-03 (Trodelvy vs Chemo) – primary outcomes (287 Data points from trial reports【7†L29-L38 (^[10])).

Data sources: Daiichi press releases and publications of TROPION-Breast02 (^[1]) (^[27]); Gilead press on ASCENT-03 (^[28]).

Safety: Treatment-emergent toxicity was generally manageable and consistent with known ADC profiles. Grade ≥3 treatment-related AEs occurred in 33% (Datroway) vs 29% (chemo) of patients (^[5]). The most common serious AEs on Datroway were neutropenia, stomatitis, fatigue, anemia or vomiting, but importantly discontinuation rates due to AEs were lower on Datroway (4%) than on chemo (7%) (^[5]). Notably, no treatment-related deaths occurred in the Datroway arm (per the Journal article) (^[5]) (the FDA noted one adjudicated ILD-grade 5 attributed to progression). Overall, the safety profile was reported as favorable – a single-dose level (6 mg/kg Q3W), with infrequent severe toxicities.

Statistical Considerations: The co-primary endpoints (PFS, OS) were pre-planned with the strong PFS improvement allowing formal testing of OS (hierarchical procedures). The OS p-value (0.029) crossed the standard 0.05 threshold (with a nominal 0.031 cut-off due to dual endpoints), satisfying significance (^[27]). The hazard ratio of 0.79 corresponds to a 21% reduction in mortality risk with Datroway. (By contrast, sacituzumab’s ASCENT-03 trial only met PFS but did not demonstrate an OS benefit at interim analysis (^[2]).) The robust OS data were highlighted by both companies as unique among ADCs in this setting (^[11]) (^[2]).

Benchmarks: These outcomes represent a major advance. As Dr. Rebecca Dent (TROPION-Breast02 Chief Investigator) concluded, “The TROPION-Breast02 data support Dato-DXd as a new standard of care in first-line metastatic TNBC for patients ineligible for immunotherapy. The consistent benefit in OS and PFS, along with favorable safety, reinforces its potential in this population” (^[31]). Similarly, in a recent industry analysis, it was noted that Datroway is the only therapy to significantly extend OS vs chemo in any first-line TNBC trial to date (^[2]). The trial’s success is particularly striking given that more than half the patients likely had high-risk features (e.g. short disease-free interval, prior treatments) (^[32]) (^[23]), underscoring the durability of benefit.

Regulatory Pathway and Key Milestones

Datroway’s journey to approval in first-line TNBC involved multiple filings and designations across regions. Key milestones include:

• U.S. BIologic License Applications: A supplemental BLA (sBLA) was accepted by FDA on Feb 3, 2026, with Priority Review for “adult patients with unresectable or metastatic TNBC not candidates for PD-1/PD-L1 inhibitor therapy” (^[20]). The PDUFA (action) date was set for June 2, 2026. In fact, the FDA acted slightly early, granting approval on May 22, 2026 (^[21]). This was simultaneous with the merger of Datroway's OS benefit with accelerated review under Project Orbis (Australia, Canada, Singapore, Switzerland) (^[8]) (^[9]).

• FDA Designations: The submission was under Priority Review (6-month review schedule) (^[20]). Project Orbis provided a multi-national review framework; in addition to the FDA, Datroway’s applications were coordinated with international regulators (Australian TGA, Health Canada, HSA Singapore, Swissmedic) (^[8]) (^[9]). These programs aim to expedite approval globally for important oncology therapies. The FDA noted Datroway’s strong efficacy (improved survival) warranted expedited consideration.

• History of Approvals: Datroway’s first U.S. approval was Jan 17, 2025 for “previously treated metastatic HR+ (HER2-) breast cancer” (based on TROPION-Breast01) (^[33]). Its second approval was on June 23, 2025 for EGFR-mutated NSCLC based on non-OS endpoints (^[19]). Thus, in less than 18 months, Datroway expanded from one to three indications in oncology (^[19]) (^[33]).

• Label Indication (TNBC): The new FDA label (DLT-60522) indicates Datroway for “adult patients with locally advanced or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy” (^[21]). In practice, this means first-line therapy of TNBC patients either PD-L1-negative or unable to receive immunotherapy. The recommended dosing is 6 mg/kg IV every 3 weeks (up to 540 mg) until progression or toxicity.

• EU and Other Regions: In Europe, a Type II variation application to extend Datroway’s marketing (originally HR+ indication) to include first-line TNBC (same criteria) was validated by EMA on Dec 18, 2025 (^[6]). Validation marks the start of CHMP review. If approved (expected mid-2026), Datroway could become EU’s first frontline ADC for TNBC. Regulatory submissions in other markets (e.g. China, Japan) are also pending; global filings are planned, leveraging the positive Phase III data (^[34]) (^[9]).

【Table 2: Regulatory Milestones for Datroway (Datopotamab Deruxtecan). Charting Datroway’s key FDA approvals and recent submissions (by indication).

Sources: Company press releases, FDA announcements, and businesswire/Media reports (^[33]) (^[19]) (^[6]) (^[9]) (dates represent official FDA actions or EMA MAA events).

Comparison with Other TROP2 ADCs in Frontline TNBC

Datroway’s approval comes amid a “TROP2 ADC race” in first-line TNBC. The main comparator is sacituzumab govitecan (Trodelvy, a TROP2-ADC marketed by Gilead). Trodelvy is approved in ≥2L TNBC, but recently reported positive Phase III data in the first-line PD-1–ineligible population. In the ASCENT-03 trial (n≈600), planned similarly to TROPION-Breast02, Trodelvy showed a median PFS of 9.7 vs 6.9 mo over chemo (HR=0.62, p<0.0001) (^[28]) and ORRs ~48% vs 46% (^[28]). ASCENT-03 met its primary PFS endpoint, but its OS data are immature; early reports noted “no OS detriment” at interim (^[35]) (^[13]). By cross-trial comparison, Datroway’s 43% PFS risk reduction (HR 0.57) is numerically larger than Trodelvy’s 38% (HR 0.62) (^[36]), and Datroway uniquely achieved an OS benefit.

Both ADCs are being positioned for 1L TNBC use. In fact, even before FDA’s May 2026 decision, the NCCN breast cancer guidelines added both datopotamab and sacituzumab as Category 1 preferred regimens for first-line TNBC (PD-1–ineligible) (^[37]). However, analysts note differences: Datroway will market itself on the franchise’s first OS-proving data (^[36]) (^[11]), whereas Gilead is pursuing multiple approvals (Trodelvy + pembrolizumab in PD-L1+ first-line, and behind-the-scenes seniority of trodelvy familiarity). Importantly, Gilead reported some uptake of Trodelvy in first-line following guideline inclusion (^[38]), indicating real-world deviation toward TROP2 ADC therapy even before Datroway’s FDA nod.

A third TROP2 ADC (sacituzumab deruxtecan by Merck/Kelun Biotech, under development in Asia) also showed a positive first-line TNBC data (OpTiTROP-Breast03 study in PD-L1–negative disease) around the same time (^[39]). Several trials (e.g. Phase III TroFuse-011) are testing combinations of these ADCs with pembrolizumab. In this context, Datroway’s clear survival benefit provides a strategic advantage and likely a headstart in shaping frontline standards.

Launch Strategy & Market Access Considerations

Target Patient Population: The indication covers roughly the 60–70% of metastatic TNBC patients who cannot receive PD-1/L1 therapy (^[6]) (^[7]). (This includes all PD-L1-negative tumors and a subset of PD-L1-positive who are ineligible or pre-treated with immunotherapy.) These patients historically receive single-agent chemotherapy. Given the poor outcomes with chemo (median OS <20 months) (^[1]), Datroway offers a much needed improvement. The estimated population in the US might be on the order of 3,000–4,000 new patients per year (assuming ~30,000 metastatic TNBC diagnoses annually and ~70% being PD-1–ineligible) (^[6]). Globally, the market could be several times larger. Analysts have pointed to a ~$500 million annual market opportunity for Datroway in TNBC (^[40]), roughly comparable to the existing sacituzumab TNBC market.

Pricing and Value: Datroway’s price in other indications provides a benchmark. In the HR+ breast cancer market, Datroway’s list price has been reported as roughly $4,891 per vial (April 2025 data) (^[41]). At a 6 mg/kg dose, a typical 60–80 kg patient might use 400–480 mg (4–5 vials) per infusion. This is in line with current ADC pricing (e.g. sacituzumab is ~$17,300/dose of 10 mg/kg, or Enhertu ~$34,000/month). Payers will evaluate cost-effectiveness in terms of incremental life-months gained. Datroway’s strong OS benefit in a disease that otherwise has limited options supports a premium price. It will likely be priced similarly to or slightly below Enhertu and trodelvy. (For reference, analysts have estimated Datroway’s peak US sales in its initial HR+ indication around $540 million (^[42]). The TNBC expansion could potentially double the addressable scenario.) AstraZeneca and Daiichi will need to negotiate with CMS and private insurers on reimbursement pathways; given FDA approval and category-1 NCCN listing, access hurdles should be fewer.

Formulary and Reimbursement: As a specialty oncology therapy, Datroway requires prior authorization. Payors will require confirmation of diagnosis (TNBC), prior treatment history (no prior metastatic therapy), and exclusion of PD-1 inhibitors. PD-L1 testing is already routine to guide pembrolizumab use, which will help categorize patients. For patients with borderline eligibility (e.g. prior early use of immunotherapy), real-world on-label use could depend on subtle factors. Importantly, commercial and Medicare plans will compare Datroway to the cost of existing first-line regimens. A once-every-3-week infusion regimen with improved survival is likely to be deemed cost-effective given the OS gains. Companion drug VTE/ILD monitoring costs will also be considered. Companies often offer patient assistance and outcomes-based contracting; such programs may facilitate uptake.

Guideline and Oncologist Strategy: AstraZeneca/Daiichi will emphasize Datroway’s practice-changing data to oncologists and tumor boards. Key opinion leaders (KOLs) will highlight the “first chemo replacement” for PD-1–ineligible TNBC, referencing the OS improvement. Medical affairs will train community oncologists on infusion protocols and safety monitoring (ocular exams, stomatitis prophylaxis, ILD vigilance). Early-adopter centers (academic cancer centers) will lead usage. Marketing will likely bundle Datroway with TROPION-Breast02 data slides, headlining the 5-month OS advantage (^[43]). Patient advocacy groups (e.g. TNBC Foundation) have already praised the approval (^[7]), and will help inform patients of new options.

Competitive Positioning: Datroway is entering a market where Gilead’s Trodelvy is also vying for first-line use. Given Prelude (datroway’s superior OS data) and a strong overall efficacy profile, AstraZeneca/Daiichi will position Datroway as the preferred TROP2-ADC. Pricing will factor in competition but the companies will stress value (life-year gain). Gilead, in contrast, will likely seek label expansion for Trodelvy (both monotherapy and combo) in 2026. The companies might also explore combination trials (e.g. Datroway + pembrolizumab, mirroring ASCENT-04) to capture PD-L1+ patients.

Market Access Challenges: Potential hurdles include: securing reimbursement as “first-line therapy” (a shift from chemo), educating oncologists accustomed to chemo-first, and addressing safety monitoring burdens. The ILD risk (rare but serious) will require systems for early detection. Europe will follow FDA’s lead; however, EMA approval may come later in 2026, delaying EU access. In Japan and China, regulatory timelines are pending, and market access in those large countries will involve local health technology assessments (HTAs). For instance, Japan may require a separate BRIDAL or DECISION; Daiichi has a strong presence there and may expedite review.

Real-World Case Vignettes:

• Physician Perspective: In updated NCCN guidelines, Datroway was placed as a category 1 option for first-line TNBC lacking PD-L1 options (^[37]). Dr. Arlene Brothers (TNBC Foundation) noted that “today’s approval means for the first time, [these] patients will have a new standard of care beyond traditional chemotherapy” (^[7]). This reflects a consensus shift among experts: whereas chemo was “default,” now a targeted ADC is available. Oncologists will integrate Datroway by identifying eligible patients up front and ordering PD-L1 testing promptly to stratify therapy.

• Patient Perspective: For a newly-diagnosed TNBC patient deemed PDL1-negative, the typical plan was chemo only (with median survival ~19 months). With Datroway, this patient can receive an ADC infusion every 3 weeks, hoping for a response (observed in ~60% of such patients) and significantly delayed progression. Patient advocates highlight that this is the first time such patients have an OS-prolonging option, potentially meaning months more life and better quality of life than chemo alone.

• Health System Perspective: A large cancer center analyzing its cost structure will note that up-front Datroway therapy, though high-cost drug, can reduce hospitalizations (fewer chemo complications) and extend survival. The center’s pharmacy will prepare protocols for Datroway compounding. Payer panels may convene to review the trial data; based on evidence, Medicare is likely to cover this indication nationally due to the Category 1 NCCN endorsement.

Discussion of Implications and Future Directions

Datroway’s approval is a pivotal moment in breast cancer therapeutics. It validates the TROP2-targeted ADC concept in a challenging, underserved population. The immediate implication is that frontline TNBC treatment algorithms will almost certainly change. Instead of “chemo alone” for PD-1–ineligible patients, Datroway plus chemo (or Datroway alone vs chemo) will be a qualifying regimen. The clinical community now has a biomarker-driven dichotomy: PD-L1-positive TNBC (for whom immunotherapy combos are indicated) and PD-L1-negative TNBC (where Datroway adds a targeted option).

Guideline and Practice Impact: Professional guidelines (NCCN, ESMO) will be updated. Notably, NCCN has already listed Datroway/Trodelvy in 1L TNBC (^[37]) even before FDA action; FDA approval cements category 1 status and opens the door for worldwide guideline endorsements. The change will permeate tumor boards and insurance policies; Datroway will become a listed standard.

Patient Stratification: An important question is how strictly PD-L1-negativity will be enforced. In trials, Datroway improved survival regardless of PD-L1 status, but the label restricts to those “not candidates” for PD-1. In practice, some PD-L1+ patients who cannot tolerate immunotherapy (autoimmune, prior therapy, comorbidities) will be treated with Datroway. Over time, physicians may even consider off-label Datroway in PD-L1+ patients at borderline. Future studies may address combining Datroway with immunotherapy to cover all PD-L1 subgroups.

Further Clinical Development: AstraZeneca/Daiichi and peers will likely explore combination regimens. Ongoing trials include Datroway + pembrolizumab in TNBC (mirroring Gilead’s ASCENT-04) and earlier-stage settings (neoadjuvant/adjuvant TNBC). If Datroway moves into earlier lines, this raises issues of sequencing (e.g. if a patient on Datroway relapses, do they get Trodelvy or other ADC?). Long-term follow-up will assess survival beyond second-line. Collaboration or head-to-head comparisons between ADCs are unlikely, but real-world data will eventually compare survival with Datroway vs Trodelvy usage patterns.

Long-term Outlook: Over the next decade, TROP2 ADCs may become a class of care in TNBC as HER2-ADCs did in HER2-positive disease. There is also interest in bispecific antibodies or novel payloads. For AstraZeneca/Daiichi, Datroway’s success boosts their oncology franchise (they have highlighted 20 drugs to reach $80B sales (^[44])). The companies aim for “global top 5 in oncology by 2035” (^[45]), and Datroway in TNBC is a key driver. For patients, the future indeed looks brighter for an ailment long lacking targeted therapies.

Conclusion

The FDA’s June 2026 approval of Datroway for first-line metastatic TNBC (in PD-1/L1–ineligible patients) marks a significant advance in this aggressive disease area. The TROPION-Breast02 data demonstrated robust improvements in survival and response compared to standard chemotherapy (^[1]) (^[27]), setting a new benchmark for therapeutic effect. AstraZeneca and Daiichi Sankyo now have the first approved ADC that prolongs OS in frontline TNBC, with a clear pathway to expand global access. The companies face the challenge of competitively launching Datroway — addressing issues of pricing, payer acceptance, and oncology practice change — but the clinical need and compelling evidence strongly support uptake.

This report has examined the historical context, trial evidence, regulatory developments, and market considerations surrounding Datroway’s TNBC approval. We provided detailed data from TROPION-Breast02 and other studies (^[1]) (^[28]) (^[27]), discussed launch and access strategies with analogous examples (Trodelvy, Enhertu) (^[33]) (^[46]), and highlighted expert views and case examples (^[31]) (^[7]). As the oncology community integrates Datroway into practice, continued evaluation will determine how much it improves patient outcomes in the messy real world. But for now, Datroway’s approval represents a major milestone: for many patients with metastatic TNBC, first-line treatment is no longer limited to chemotherapy alone.

References: (All cited data and statements are from publicly available sources and publications as noted inline, including FDA/FDA.gov, Daiichi/AZ press releases, peer-reviewed journals, and reputable news/analyses (^[1]) (^[27]) (^[46]).)